Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator-initiated trial evaluating the efficacy and safety of Valixa® in children with symptomatic congenital cytomegalovirus infection (VGCV-1)

Next Previous
Trial Profile

An investigator-initiated trial evaluating the efficacy and safety of Valixa® in children with symptomatic congenital cytomegalovirus infection (VGCV-1)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalovirus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms VGCV-1
  • Sponsors Mitsubishi Tanabe Pharma Corporation

Most Recent Events

  • 08 Jul 2022 New trial record
  • 30 Jun 2022 According to a Mitsubishi Tanabe Pharma Corporation media release, based on the data from this study, company filed an application for an additional indication of the anti-cytomegalovirus agent Valixa Dry Syrup 5000mg, for the treatment of symptomatic congenital cytomegalovirus infection in Japan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top